Magazine Article | August 2, 2018

Samsung Bioepis: Applying The "Hunger" For Biosimilars To Novel Drugs

Source: Life Science Leader

By Anna Rose Welch, Director, Cell & Gene Collaborative

In February 2017, I found myself in Philadelphia interviewing a VP at Samsung Bioepis about the company’s efforts to establish its process innovation. It was this process that enabled the company to have three biosimilars approved in Europe, two submitted for EMA review and one for FDA review — all in five brief years.

Today the company has seen all of its biosimilars under European review approved, and a majority of them have been launched, including Europe’s first Herceptin biosimilar. In the past year, the company also announced its partnership with Takeda to codevelop novel biologics. So, when I realized Brian Hosung Min, an SVP and head of drug substance at Samsung Bioepis, would be presenting at the World Biosimilars Congress in San Diego in May of this year, I jumped at the opportunity to see how far the company and its process innovation had progressed. Over lunch, Min explained the company’s ongoing efforts to realize a lower cost of goods sold (COGS), speed up production, and manage risk in biosimilar and novel biologics development.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: